23 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
25079952	38	Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy.	University of California Davis
25800114	20	Three-dimensional rational approach to the discovery of potent substituted cyclopropyl urea soluble epoxide hydrolase inhibitors.	Sumitomo Dainippon Pharma
24530032	65	Structure-based optimization of cyclopropyl urea derivatives as potent soluble epoxide hydrolase inhibitors for potential decrease of renal injury without hypotensive action.	Dainippon Sumitomo Pharma
24373724	47	Discovery of 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating of chronic kidney diseases.	Toray Industries
24035338	82	Discovery of 2,8-diazaspiro[4.5]decane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating hypertension.	Toray Industries
23664879	73	Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.	Glaxosmithkline
21354674	14	The many faces of the adamantyl group in drug design.	University of Sydney
21192659	16	A practical use of ligand efficiency indices out of the fragment-based approach: ligand efficiency-guided lead identification of soluble epoxide hydrolase inhibitors.	Dainippon Sumitomo Pharma
19645482	245	Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.	Merck Research Laboratories
17616115	61	Orally bioavailable potent soluble epoxide hydrolase inhibitors.	University of California Davis
20472432	29	Rapid synthesis of an array of trisubstituted urea-based soluble epoxide hydrolase inhibitors facilitated by a novel solid-phase method.	Boehringer Ingelheim Pharmaceuticals
19682899	211	Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.	Merck Research Laboratories
19969453	73	Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase.	Boehringer Ingelheim Pharmaceuticals
19758802	56	Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase.	Boehringer Ingelheim Pharmaceuticals
19700315	68	A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors.	Merck Research Laboratories
19746975	67	Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.	Boehringer Ingelheim Pharmaceuticals
19481932	164	Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.	Merck Research Laboratories
31436984	54	Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain.	Goethe-University Frankfurt
29366648	98	Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.	University of California Davis
29803731	68	Adamantyl thioureas as soluble epoxide hydrolase inhibitors.	University of California Davis
29614224	27	Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain.	University of California Davis